Rhythm Pharmaceuticals Inc (RYTM)
NASDAQ:RYTM
Want to see RYTM full AI Analyst Report?
RYTM Stock Chart & Stats
$88.69
-$0.41(-0.68%)
At close: 4:00 PM EST
$88.69
-$0.41(-0.68%)
Day’s Range― - ―
52-Week Range$55.31 - $122.20
Previous CloseN/A
Volume91.33K
Average Volume (3M)909.06K
Market Cap
$5.56B
Enterprise Value$5.80B
Total Cash (Recent Filing)$388.95M
Total Debt (Recent Filing)$246.47M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
May 05, 2026EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.73
Shares Outstanding68,285,040
10 Day Avg. Volume615,533
30 Day Avg. Volume909,064
Financial Highlights & Ratios
PEG Ratio1.25
Price to Book (P/B)50.02
Price to Sales (P/S)36.66
P/FCF Ratio-59.64
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue30.56
Enterprise Value/Gross Profit34.06
Enterprise Value/Ebitda-33.31
Forecast
1Y Price Target
$136.23Price Target Upside53.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-3.07
Revenue Forecast (FY)$287.89M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPivotal trial data demonstrated meaningful reductions in weight and hunger with generally favorable tolerability, supporting the drug's potential to become a new standard of care for acquired hypothalamic obesity.
Commercial PreparednessA targeted commercial plan that expands the sales force, leverages prior payer-education experience, and uses a country-by-country European rollout increases the likelihood of effective market entry and reimbursement progress.
Regulatory StatusFDA approval as the first and only therapy for acquired hypothalamic obesity establishes a unique product position in an underserved market and supports a clear regulatory footing for commercial efforts.
Bears Say
Market Adoption UncertaintyA smaller-than-expected addressable population and challenges securing a dedicated diagnosis code or broad clinical recognition could slow uptake and limit commercial performance.
Reimbursement RiskAdoption will depend heavily on payer authorization and coverage decisions, making reimbursement uncertainty a key constraint on patient access and revenue potential.
Safety And TolerabilityLabel warnings about adrenal insufficiency and sodium imbalance, along with common adverse effects like skin hyperpigmentation and nausea, may complicate treatment management and reduce prescribing enthusiasm.
Rhythm Pharmaceuticals News
RYTM FAQ
What was Rhythm Pharmaceuticals Inc’s price range in the past 12 months?
Rhythm Pharmaceuticals Inc lowest stock price was $55.31 and its highest was $122.20 in the past 12 months.
What is Rhythm Pharmaceuticals Inc’s market cap?
Rhythm Pharmaceuticals Inc’s market cap is $5.56B.
When is Rhythm Pharmaceuticals Inc’s upcoming earnings report date?
Rhythm Pharmaceuticals Inc’s upcoming earnings report date is May 05, 2026 which is in 4 days.
How were Rhythm Pharmaceuticals Inc’s earnings last quarter?
Rhythm Pharmaceuticals Inc released its earnings results on Feb 26, 2026. The company reported -$0.73 earnings per share for the quarter, beating the consensus estimate of -$0.805 by $0.075.
Is Rhythm Pharmaceuticals Inc overvalued?
According to Wall Street analysts Rhythm Pharmaceuticals Inc’s price is currently Undervalued.
Does Rhythm Pharmaceuticals Inc pay dividends?
Rhythm Pharmaceuticals Inc does not currently pay dividends.
What is Rhythm Pharmaceuticals Inc’s EPS estimate?
Rhythm Pharmaceuticals Inc’s EPS estimate is -0.83.
How many shares outstanding does Rhythm Pharmaceuticals Inc have?
Rhythm Pharmaceuticals Inc has 68,285,040 shares outstanding.
What happened to Rhythm Pharmaceuticals Inc’s price movement after its last earnings report?
Rhythm Pharmaceuticals Inc reported an EPS of -$0.73 in its last earnings report, beating expectations of -$0.805. Following the earnings report the stock price went down -1.089%.
Which hedge fund is a major shareholder of Rhythm Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in RYTM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rhythm Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$136.23 (53.60% Upside)
$136.23 (53.60% Upside)
Blogger Sentiment
Bullish
RYTM Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 99.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $502.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 2.5%
Last 30 Days ▲ 5.2%
Last 30 Days ▲ 5.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
43.65%
12-Months-Change
Fundamentals
Return on Equity
-179.05%
Trailing 12-Months
Asset Growth
22.29%
Trailing 12-Months
Company Description
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
RYTM Company Deck
RYTM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced strong commercial momentum, meaningful year-over-year revenue growth (~+50% FY), expanding international footprint, positive longer-term clinical signals (notably durable bivamelagon 40-week BMI reductions and FDA EOP2 confirmation to proceed to Phase 3), and a healthy cash runway (~$389M) against several operational and development headwinds: FDA-mandated larger/longer trials for new chemical entities (which may extend timelines and cost), inventory dynamics that may dampen near-term revenue, rising operating expenses (2026 non-GAAP OpEx guide ~+35% vs 2025), and remaining uncertainties in genetic substudies and reimbursement timing. Overall the company appears well-capitalized and advancing multiple programs and launches, but will absorb near-term expense and execution risk as it scales.View all RYTM earnings summariesRYTM Stock 12 Month Forecast
Average Price Target
$136.23
▲(53.60% Upside)
Technical Analysis
Cytokinetics
―
TG Therapeutics
―
Legend Biotech
―
Atrium Therapeutics, Inc.
―
Abivax SA Sponsored ADR
―
Ownership Overview
0.82% Insiders
31.62% Mutual Funds
0.91% Other Institutional Investors
51.34% Public Companies and
Individual Investors